Shares of Selecta Biosciences Inc (NASDAQ:SELB) have been assigned a consensus broker rating score of 0.00 () from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company.
Analysts have set a 12-month consensus price target of $26.67 for the company and are anticipating that the company will post $0.32 EPS for the current quarter, according to Zacks. Zacks has also assigned Selecta Biosciences an industry rank of 106 out of 265 based on the ratings given to related companies.
Several research firms have commented on SELB. Zacks Investment Research raised shares of Selecta Biosciences from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research report on Friday, December 9th. Stifel Nicolaus reissued a “buy” rating and set a $32.00 price target (up from $23.00) on shares of Selecta Biosciences in a research report on Thursday, December 8th. Finally, Canaccord Genuity set a $25.00 price target on shares of Selecta Biosciences and gave the company a “buy” rating in a research report on Tuesday, December 6th.
Selecta Biosciences (NASDAQ:SELB) opened at 12.04 on Monday. Selecta Biosciences has a 12-month low of $10.26 and a 12-month high of $28.00. The company has a 50 day moving average of $13.31 and a 200-day moving average of $16.50.
In other news, insider Takashi Kei Kishimoto sold 10,000 shares of the company’s stock in a transaction dated Wednesday, December 28th. The shares were sold at an average price of $17.55, for a total transaction of $175,500.00. Following the transaction, the insider now owns 10,000 shares in the company, valued at $175,500. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Several institutional investors have recently bought and sold shares of SELB. Deerfield Management Co. purchased a new position in shares of Selecta Biosciences during the fourth quarter valued at about $14,632,000. Sphera Funds Management LTD. purchased a new position in shares of Selecta Biosciences during the third quarter valued at about $3,989,000. Baker BROS. Advisors LP purchased a new position in shares of Selecta Biosciences during the third quarter valued at about $2,550,000. Perceptive Advisors LLC purchased a new position in shares of Selecta Biosciences during the fourth quarter valued at about $2,433,000. Finally, State Street Corp purchased a new position in shares of Selecta Biosciences during the fourth quarter valued at about $1,195,000. Hedge funds and other institutional investors own 41.74% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Web Breaking News and is the property of of Web Breaking News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at http://www.webbreakingnews.com/2017/03/25/selecta-biosciences-inc-selb-receives-consensus-recommendation-of-from-analysts.html.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.